AIM CEO Corner AIM CEO Corner CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline…
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…
Company announces new partners including The University of Texas and Rising Pharmaceuticals FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) --…
Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR)…
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),…
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.…
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug…
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high…
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income…
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in…